Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2025-04-25 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising (募集资金) management and actual usage for the year 2024. It includes specifics on the amount raised, usage against projects, cash management of idle funds, regulatory compliance, and auditor and sponsor institution opinions. The document references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and it is titled as a "专项报告" (special report) on fundraising funds storage and usage. This type of document is a specialized report on capital/fundraising activities rather than a general annual or interim financial report. It does not contain full financial statements or earnings data but focuses on the management and use of raised capital. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6497 characters) and detailed financial figures support it being a substantive report rather than a brief announcement or certification. Hence, the classification is CAP with high confidence.
2025-04-25 Chinese
赛伦生物：2024年度内部控制审计报告
Regulatory Filings
2025-04-25 Chinese
赛伦生物：2024年度独立董事述职报告（傅以尚）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 from Shanghai Sairen Biotechnology Co., Ltd. It details the independent director's duties, attendance at board and committee meetings, communication with auditors, evaluation of financial reports, and other governance-related activities during the year. The content focuses on the independent director's oversight and compliance with legal and governance requirements rather than presenting financial statements or audit results themselves. The document length is 3890 characters, which is relatively short and more consistent with a report or statement rather than a full annual report or audit report. It is not a certification or a brief announcement but a detailed narrative of the independent director's work and observations. This type of document fits best under Board/Management Information (MANG), as it relates to board activities and management oversight rather than financial results or audit opinions.
2025-04-25 Chinese
赛伦生物：未来三年（2025-2027年）股东分红回报规划
Notice of Dividend Amount Classification · 95% confidence The document is a detailed plan regarding the company's shareholder dividend distribution policy for the years 2025-2027. It outlines principles, conditions, proportions, decision-making procedures, and adjustment mechanisms related to dividends and shareholder returns. It is not a financial report, earnings release, or regulatory filing but a formal announcement of the company's dividend policy and shareholder return plan. This type of document fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend distribution planning and shareholder returns over a multi-year period.
2025-04-25 Chinese
赛伦生物：2024年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度董事会审计委员会履职情况报告" which translates to "2024 Annual Report on the Board Audit Committee's Performance." It details the audit committee's activities, meetings, supervision of external auditors, internal audit guidance, review of financial reports, internal control evaluation, and overall assessment of their duties during the year 2024. The content focuses on the audit committee's work and oversight rather than presenting full financial statements or a comprehensive annual report. It is a specialized report on audit committee activities, which aligns with the category of Audit Report / Information (AR). The document length is 2594 characters, which is relatively short but contains substantive information about audit committee duties and evaluations, not just an announcement or certification. Therefore, it is classified as an Audit Report / Information (AR). FY 2024
2025-04-25 Chinese
赛伦生物：2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度会计师事务所履职情况评估报告" which translates to "2024 Annual Evaluation Report on the Performance of the Accounting Firm." It details the qualifications, independence, quality control, and performance of the auditing firm Tianzhi International in relation to the company's 2024 annual audit. The content focuses on the audit firm's credentials, personnel, independence, quality management, and overall evaluation of their audit work for the 2024 annual report. It does not contain the actual financial statements or the full annual report of the company itself, but rather an evaluation of the auditor's performance. This type of document is a standalone audit-related report, not the full Annual Report (10-K) or an announcement. It fits the category of Audit Report / Information (AR). The document length is under 5,000 characters but it is a substantive report, not a mere announcement of a report publication, so it is not RPA. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.